



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/801,944	03/08/2001	Gabriel Vogeli	PHRM0008-100/00100.US1	5364
26657	7590	05/11/2004	EXAMINER	
WOODCOCK WASHBURN KURTZ MACKIEWICZ & NORRIS LLP ATTENTION: SUZANNE E. MILLER ESQ. ONE LIBERTY PLACE, 46TH FLOOR PHILADELPHIA, PA 19103			LI, RUIXIANG	
			ART UNIT	PAPER NUMBER
			1646	

DATE MAILED: 05/11/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/801,944

Applicant(s)

VOGELI ET AL.

Examiner

Ruixiang Li

Art Unit

1646

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-95 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☐ Claim(s) ____ is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☒ Claim(s) 1-95 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. ____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____. |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date ____. | 6) <input type="checkbox"/> Other: ____. |

Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-29, 67-72, and 82-87, drawn to an isolated nucleic acid, a vector, a host cell, and a method of producing a polypeptide, classified in class 536, subclass 23.5 and class 435, subclass 320.1, 325, and 69.1.
 - II. Claims 30-35 and 88-90, drawn to an isolated polypeptide, classified in class 530, subclass 350.
 - III. Claims 36-38 and 91, drawn to an antibody, classified in class 530, subclass 387.9.
 - IV. Claims 39, drawn to a method for of inducing an immune response in a mammal against a polypeptide of claim 30, classified in class 424, subclass 185.1.
 - V. Claims 40-43, 74, 76 (in part), 77 (in part), and 92, drawn to a method for identifying a compound which binds nGPCR-x, classified in class 435, subclass 7.1.
 - VI. Claim 44, drawn to a compound identified by the method of claim 40, classification depends upon the structure of the compound.
 - VII. Claims 45-47, drawn to a method for identifying a compound which binds a nucleic acid molecule encoding nGPCR-x, classified in class 435, subclass 6.
 - VIII. Claims 48-51, 73, 93, and 94, drawn to a method for identifying a compound which modulates the activity of nGPCR-x, classified in class 435, subclass 4.

Art Unit: 1646

- IX. Claim 52, drawn to a compound identified by the method of claim 48, classification depends upon the structure of the compound.
- X. Claims 53-55, drawn to a method of identifying an animal homolog of nGPCR-x, classified in class 436, subclass 250.
- XI. Claims 56-65 and 95, drawn to a method of screening a human subject to diagnose a disorder affecting the brain or genetic predisposition, classified in class 435, subclass 6.
- XII. Claim 66, drawn to a method of identifying a nGPCR-x allelic variant that correlates with a mental disorder, classified in class 435, subclass 6.
- XIII. Claims 75, 76 (in part), and 77 (in part), drawn to a method for identifying a compound useful as a modulator of binding between nGPCR-x and a binding partner of nGPCR-x, classified in class 435, subclass 7.1.
- XIV. Claim 78-81, drawn to a method of purifying a G protein from a sample, classified in class 435, subclass 7.1.
- 2. The inventions are distinct, each from the other for the following reasons. Inventions I-III, VI, and IX are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP §806.04, MPEP §808.01). In the instant case, the different inventions are drawn to completely different products, nucleic acid molecules, polypeptides, and antibodies. These molecules have completely different structures and biological functions which are not interchangeable and which require non-cohesive

searches and considerations. The compounds of Inventions VI and IX are to be identified by the method of claim 40 or claim 48 and their structures remain to be determined.

3. Inventions IV, V, VII, VIII, X-XIV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP §806.04, MPEP §808.01). In the instant case, the different inventions are drawn to completely different methods each having completely different method steps, using different compositions, and having completely different outcomes. Invention IV requires inducing an immune response in a mammal against a polypeptide of claim 30, Invention V requires identifying a compound which binds nGPCR-x, Invention VII requires identifying a compound which binds a nucleic acid encoding nGPCR-x, invention VIII requires identifying a compound which modulates the activity of nGPCR-x, Invention X requires identifying an animal homolog of nGPCR-x, Invention XI requires screening a human subject to diagnose a disorder affecting the brain or genetic predisposition, Invention XII requires identifying a GPCR-x variant that correlates with a mental disorder, Invention XIII requires identifying a compound useful as a modulator of binding between nGPCR-x and a binding partner of nGPCR-x, whereas invention XIV requires purifying a G protein from a sample. Each method is unique and not required for another. Thus, the methods are exclusive and require non-cohesive searches and considerations.

Art Unit: 1646

4. Inventions I-III, VI and IX and Inventions IV, V, VII, VIII, and X-XIV are either related as product and process of use or are drawn to distinct product and method inventions. In the case that the inventions are related as product and process of use, the inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP §806.05 (h)). For example, a nucleic acid may be used in a materially different process such as production of a polypeptide; a polypeptide may be used in a materially different process such as to immunize mice to produce an antibody; an antibody may be used in a materially different process such as to immunoprecipitate or purify a polypeptide.
5. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.
6. Because these inventions are distinct for the reasons given above and the search required for a single group is not required for any other group, restriction for examination purposes as indicated is proper.
7. Furthermore, the application contains claims which are directed to numerous amino acid/nucleic acid sequences as represented by different SEQ ID NOS. Each individual sequence represents a structural and functionally distinct entity that is capable of supporting a separate patent. The search and consideration of more

Art Unit: 1646

than a single sequence constitutes an undue search burden on the office, given the ever-increasing size of the database.

Applicant is advised that a reply to this requirement must include an identification of an amino acid/ nucleic acid sequence that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election. **The Examiner notes that this is not a species election requirement; rather it sets forth additional invention groups.**

8. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. **Process claims that depend from or otherwise include all the limitations of the patentable product** will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the

Art Unit: 1646

requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai*, *In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.** Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Advisory Information

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48 (b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48 (b) and by the fee required under 37 CFR 1.17 (I).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ruixiang Li whose telephone number is (571) 272-0875. The examiner can normally be reached on Monday-Friday, 8:30 am-5:00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler, can be reached on (571) 272-0871. The fax number for this Group is (703) 872-9306.

Communications via Internet e-mail regarding this application, other than those under 35 U.S.C. 132 or which otherwise require a signature, may be used by the applicant and should be addressed to [yvonne.eyler@uspto.gov]. All Internet e-mail communications will be made of record in the application file. PTO employees do not engage in Internet communications where there exists a possibility that sensitive information could be identified or exchanged unless the record includes a properly signed express waiver of the confidentiality requirements of 35 U.S.C. 122. This is more clearly set forth in the Interim Internet Usage Policy published in the Official Gazette of the Patent and Trademark on February 25, 1997 at 1195 OG 89.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (571) 272-1600.

Ruixiang Li

Ruixiang Li, Ph.D.
Examiner
May 10, 2004